Julie Fox
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Julie Fox has a total of 585 co-authors. Here are the top co-authors by number of shared publications:
- Sarah Fidler
NIHR Imperial Biomedical Research Centre, Imperial College London, London, UK
14 shared publications - Janet Seeley
Africa Health Research Institute
6 shared publications - Andrew Sentoogo Ssemata
London School of Hygiene and Tropical Medicine
5 shared publications - John Frater
Nuffield Department of Medicine, University of Oxford, Oxford, UK
5 shared publications - Emily L. Webb
MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda
4 shared publications - Janan Janine Dietrich
Perinatal HIV Research Unit (PHRU), Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
4 shared publications
Latest Publications
- Open Access
- 1 December 2026
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 101 (12) , 1373-1377
Brief Report: Associations Between Pain, Mobility, Quality of Life, and Mental Health in People of Black Ethnicities With HIV in London
Background: Chronic pain, and its relationship with physical function and mental health, remains underexplored in people of Black ethnicities with HIV who experience intersecting inequities that may affect the experience and impact of pain. We investigated associations between severity of pain, physical function, and mental health in these populations. Setting: This study was conducted in 3 HIV clinics in South London, the United Kingdom Methods: We conducted a cross-sectional study in adults of Black ethnicities with HIV. Multivariable logistic regression analysis was used to examine associations between mild and moderate-severe pain, physical function, and mental health. Results: We enrolled 398 participants (median age 52 years, 55% female); 16% reported mild pain and 25% moderate-severe pain. In multivariable analysis, moderate-severe pain (vs. no pain) was associated with moderate-severely impaired mobility (adjusted odds ratio [aOR] 72.6 [25.7–250]), moderate-severely impaired ability to self-care (aOR 16.4 [4.1–111]), moderate-severely impaired ability to perform usual activities (aOR 14.9 [6.3–37.4]), and poor mental health (aOR 9.2 [5.1–17.1]) and mild pain with mild and moderate-severe impairment of mobility (aOR 6.5 [2.5–17.8] and 5.2 [1.5–18.8], respectively), mild impairment in the ability to perform usual activities (aOR 4.8 [1.9–11.9), and poor mental health (aOR 2.4 [1.2–4.8]). Conclusions: In this sample of people of Black ethnicities with HIV, two-fifths reported pain. Pain, regardless of severity, was associated with mobility impairment, difficulties performing activities of daily living, and poor mental health. We recommend evaluation of pain in HIV clinical services and establishing robust pain management pathways to maximize quality of life.
- 1 December 2026
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 101 (12) , 1373-1377
Open AccessBrief Report: Associations Between Pain, Mobility, Quality of Life, and Mental Health in People of Black Ethnicities With HIV in London
Background: Chronic pain, and its relationship with physical function and mental health, remains underexplored in people of Black ethnicities with HIV who experience intersecting inequities that may affect the experience and impact of pain. We investigated associations between severity of pain, physical function, and mental health in these populations. Setting: This study was conducted in 3 HIV clinics in South London, the United Kingdom Methods: We conducted a cross-sectional study in adults of Black ethnicities with HIV. Multivariable logistic regression analysis was used to examine associations between mild and moderate-severe pain, physical function, and mental health. Results: We enrolled 398 participants (median age 52 years, 55% female); 16% reported mild pain and 25% moderate-severe pain. In multivariable analysis, moderate-severe pain (vs. no pain) was associated with moderate-severely impaired mobility (adjusted odds ratio [aOR] 72.6 [25.7–250]), moderate-severely impaired ability to self-care (aOR 16.4 [4.1–111]), moderate-severely impaired ability to perform usual activities (aOR 14.9 [6.3–37.4]), and poor mental health (aOR 9.2 [5.1–17.1]) and mild pain with mild and moderate-severe impairment of mobility (aOR 6.5 [2.5–17.8] and 5.2 [1.5–18.8], respectively), mild impairment in the ability to perform usual activities (aOR 4.8 [1.9–11.9), and poor mental health (aOR 2.4 [1.2–4.8]). Conclusions: In this sample of people of Black ethnicities with HIV, two-fifths reported pain. Pain, regardless of severity, was associated with mobility impairment, difficulties performing activities of daily living, and poor mental health. We recommend evaluation of pain in HIV clinical services and establishing robust pain management pathways to maximize quality of life.
- Open Access
- 15 September 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (11) , 3990-4001
Broadly neutralizing antibodies in adult males living with HIV undergoing analytical treatment interruption: secondary and exploratory outcomes of the phase II randomized controlled RIO trial
RIO is an ongoing phase 2 double-blind randomized placebo-controlled human trial. Sixty-eight adult men living with human immunodeficiency virus (HIV), who were predominantly white and initiated antiretroviral therapy (ART) during primary or early-stage infection, underwent treatment interruption and were randomly assigned to a group receiving one or two doses of two long-acting broadly neutralizing antibodies (bNAbs) 3BNC117-LS and 10-1074-LS (arm A, n = 34) or saline (arm B, n = 34). The primary clinical study met its primary endpoint and was published elsewhere, demonstrating significantly delayed viral rebound and prolonged ART-free control in participants receiving bNAbs compared with placebo. The infusions were generally safe and well tolerated, with no study-related serious adverse events reported. The most common reported treatment-related adverse events were fatigue, lethargy and somnolence. Here we report on prespecified secondary analyses examining viral rebound, antibody sensitivity and reservoir dynamics, as well as prespecified exploratory analyses of rebound virus evolution and autologous antibody activity. Preinfusion reservoir measurements showed low levels of intact proviral HIV-1 DNA in circulating CD4 + T cells in both arms. The rebounding viruses in participants who received the antibodies showed significant selection for resistance to 10-1074-LS but not to 3BNC117-LS. Notably, there was a significant correlation between greater initial reservoir sensitivity to autologous antibodies and 10-1074 and time to rebound. Finally, comparison of preinfusion and prerebound HIV-1 proviral reservoir showed a decrease in intact but not defective proviruses in arm A but not in arm B. Together, these findings suggest that baseline humoral immunity and prolonged exposure to LS-bNAbs jointly shape post-treatment viral rebound dynamics in individuals who initiate ART during primary infection. ClinicalTrials.gov identifier: NCT04319367 .
- 15 September 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (11) , 3990-4001
Open AccessBroadly neutralizing antibodies in adult males living with HIV undergoing analytical treatment interruption: secondary and exploratory outcomes of the phase II randomized controlled RIO trial
RIO is an ongoing phase 2 double-blind randomized placebo-controlled human trial. Sixty-eight adult men living with human immunodeficiency virus (HIV), who were predominantly white and initiated antiretroviral therapy (ART) during primary or early-stage infection, underwent treatment interruption and were randomly assigned to a group receiving one or two doses of two long-acting broadly neutralizing antibodies (bNAbs) 3BNC117-LS and 10-1074-LS (arm A, n = 34) or saline (arm B, n = 34). The primary clinical study met its primary endpoint and was published elsewhere, demonstrating significantly delayed viral rebound and prolonged ART-free control in participants receiving bNAbs compared with placebo. The infusions were generally safe and well tolerated, with no study-related serious adverse events reported. The most common reported treatment-related adverse events were fatigue, lethargy and somnolence. Here we report on prespecified secondary analyses examining viral rebound, antibody sensitivity and reservoir dynamics, as well as prespecified exploratory analyses of rebound virus evolution and autologous antibody activity. Preinfusion reservoir measurements showed low levels of intact proviral HIV-1 DNA in circulating CD4 + T cells in both arms. The rebounding viruses in participants who received the antibodies showed significant selection for resistance to 10-1074-LS but not to 3BNC117-LS. Notably, there was a significant correlation between greater initial reservoir sensitivity to autologous antibodies and 10-1074 and time to rebound. Finally, comparison of preinfusion and prerebound HIV-1 proviral reservoir showed a decrease in intact but not defective proviruses in arm A but not in arm B. Together, these findings suggest that baseline humoral immunity and prolonged exposure to LS-bNAbs jointly shape post-treatment viral rebound dynamics in individuals who initiate ART during primary infection. ClinicalTrials.gov identifier: NCT04319367 .
- Open Access
- 1 May 2026
- Published by Elsevier in Journal of Migration and Health
- Vol. 13
Who is a mobile man ‘at risk’? Masculinity, work-related mobility, and HIV-related risks in Uganda and South Africa
- 1 May 2026
- Published by Elsevier in Journal of Migration and Health
- Vol. 13
Open AccessWho is a mobile man ‘at risk’? Masculinity, work-related mobility, and HIV-related risks in Uganda and South Africa
- Open Access
- 31 January 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Safety and biologic activity of a bispecific T cell receptor targeting HIV Gag in males living with HIV: a first-in-human trial
HIV persistence in reservoirs despite antiretroviral therapy (ART) is a barrier to a permanent cure. We present the affinity-enhanced TCR bispecific IMC-M113V as a potential therapeutic for targeted HIV reservoir elimination. Preclinical studies demonstrate that IMC-M113V redirects T cells towards cells expressing the variable viral peptide, Gag 77-85, presented by HLA-A*02:01 at low copy number, without binding to HIV-negative cells. Here, we conduct a first-in-human, open-label single ascending dose study of IMC-M113V (1.6-15 µg) in twelve HLA-A*02:01-positive males living with HIV on suppressive ART (EudraCT number 2021-002008-11). Participants receive one intravenous infusion of IMC-M113V on Day 1 and are monitored through Day 29 to evaluate safety, tolerability (primary endpoints) and pharmacodynamic (PD) activity (secondary endpoint). IMC-M113V is well tolerated and not associated with any serious adverse event. PD activity is dose-dependent and strongest in participants with highly IMC-M113V-sensitive Gag 77-85 variant sequences. Thus, we provide a promising foundation to evaluate multiple and higher doses of IMC-M113V as a strategy for achieving ART-free virological control.
- 31 January 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessSafety and biologic activity of a bispecific T cell receptor targeting HIV Gag in males living with HIV: a first-in-human trial
HIV persistence in reservoirs despite antiretroviral therapy (ART) is a barrier to a permanent cure. We present the affinity-enhanced TCR bispecific IMC-M113V as a potential therapeutic for targeted HIV reservoir elimination. Preclinical studies demonstrate that IMC-M113V redirects T cells towards cells expressing the variable viral peptide, Gag 77-85, presented by HLA-A*02:01 at low copy number, without binding to HIV-negative cells. Here, we conduct a first-in-human, open-label single ascending dose study of IMC-M113V (1.6-15 µg) in twelve HLA-A*02:01-positive males living with HIV on suppressive ART (EudraCT number 2021-002008-11). Participants receive one intravenous infusion of IMC-M113V on Day 1 and are monitored through Day 29 to evaluate safety, tolerability (primary endpoints) and pharmacodynamic (PD) activity (secondary endpoint). IMC-M113V is well tolerated and not associated with any serious adverse event. PD activity is dose-dependent and strongest in participants with highly IMC-M113V-sensitive Gag 77-85 variant sequences. Thus, we provide a promising foundation to evaluate multiple and higher doses of IMC-M113V as a strategy for achieving ART-free virological control.
- Open Access
- 26 June 2025
- Published by Wiley in Journal of the International AIDS Society
- Vol. 28 (S1) , e26511
HIV Post Exposure Prophylaxis: prospects, opportunities and challenges
- 26 June 2025
- Published by Wiley in Journal of the International AIDS Society
- Vol. 28 (S1) , e26511
Open AccessHIV Post Exposure Prophylaxis: prospects, opportunities and challenges
- Open Access
Geographical Differences in SARS-CoV-2 Antibody Response Dynamics and Neutralisation Profiles to Mild COVID-19: Lessons from a UK–Uganda Comparison
Background: The global SARS-CoV-2 pandemic revealed stark variability in clinical outcomes across populations, underscoring the need for region-tailored vaccination strategies. To inform standardised global immunisation efforts, this study compared longitudinal binding antibody responses and neutralisation capacities in mild COVID-19 cases from Uganda and the United Kingdom (UK). Methods: IgG responses to spike (S) and nucleocapsid (N) proteins, along with IgM responses to S and receptor-binding domain (RBD) proteins, were assessed in 29 Ugandan and 14 UK participants over 84 and 82 days, respectively. Antibody levels were quantified using a validated enzyme-linked immunosorbent assay (ELISA), alongside pseudovirus neutralisation assays targeting the D614G variant. Results: Ugandan participants exhibited higher early IgG and IgM levels, particularly against spike and RBD, with a rapid onset of responses that waned quickly. UK participants showed a slower but sustained increase in IgG and IgM levels. Neutralisation titres revealed elevated responses in 16.4% of Ugandan participants (>2000) compared to 4.5% of UK participants, suggesting a greater sensitivity to viral neutralisation. Conversely, 31.8% of UK participants exhibited low titres (<25) compared to 14.8% of Ugandan participants, indicating differences in resistance mechanisms. Neutralisation correlated strongly with spike and receptor-binding domain IgG in the UK cohort but showed weaker correlations in Ugandan participants. Conclusions: These findings highlight distinct population-level immune responses, suggesting that geographic factors shaped the quality and durability of SARS-CoV-2 immunity. Tailored vaccination strategies are essential to optimise immunity across diverse populations and improve global epidemic preparedness.
Open AccessGeographical Differences in SARS-CoV-2 Antibody Response Dynamics and Neutralisation Profiles to Mild COVID-19: Lessons from a UK–Uganda Comparison
Background: The global SARS-CoV-2 pandemic revealed stark variability in clinical outcomes across populations, underscoring the need for region-tailored vaccination strategies. To inform standardised global immunisation efforts, this study compared longitudinal binding antibody responses and neutralisation capacities in mild COVID-19 cases from Uganda and the United Kingdom (UK). Methods: IgG responses to spike (S) and nucleocapsid (N) proteins, along with IgM responses to S and receptor-binding domain (RBD) proteins, were assessed in 29 Ugandan and 14 UK participants over 84 and 82 days, respectively. Antibody levels were quantified using a validated enzyme-linked immunosorbent assay (ELISA), alongside pseudovirus neutralisation assays targeting the D614G variant. Results: Ugandan participants exhibited higher early IgG and IgM levels, particularly against spike and RBD, with a rapid onset of responses that waned quickly. UK participants showed a slower but sustained increase in IgG and IgM levels. Neutralisation titres revealed elevated responses in 16.4% of Ugandan participants (>2000) compared to 4.5% of UK participants, suggesting a greater sensitivity to viral neutralisation. Conversely, 31.8% of UK participants exhibited low titres (<25) compared to 14.8% of Ugandan participants, indicating differences in resistance mechanisms. Neutralisation correlated strongly with spike and receptor-binding domain IgG in the UK cohort but showed weaker correlations in Ugandan participants. Conclusions: These findings highlight distinct population-level immune responses, suggesting that geographic factors shaped the quality and durability of SARS-CoV-2 immunity. Tailored vaccination strategies are essential to optimise immunity across diverse populations and improve global epidemic preparedness.
- Open Access
- 1 February 2025
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 98 (2) , 171-175
Brief Report: Cystatin C Provides Substantially Higher Glomerular Filtration Rate Estimates Than Creatinine in a Subset of Black People With HIV on Current Antiretroviral Regimens
Background: In African populations, estimated glomerular filtration rate by cystatin C (eGFRcys) is better aligned with gold-standard GFR measurements than eGFR by creatinine (eGFRcr). Moreover, eGFRcys is unaffected by the effects of antiretroviral therapy (ART) on tubular secretion and may thus provide better estimates of GFR in people with HIV on ART. Setting: Observational cohort study of people of African ancestry living with suppressed HIV RNA on ART in London, United Kingdom. Methods: Cross-sectional analysis of 360 paired serum creatinine and cystatin C measurements. Participants whose eGFRcys substantially (>10%) exceeded eGFRcr were identified, and factors associated with this outcome were identified in logistic regression analysis. Results: The median age of participants was 52 years, 56% were women, and 82% born in Africa or the Caribbean. The eGFRcys substantially exceeded eGFRcr in 42% of participants in the overall cohort, and in 68% of those with eGFRcr 45–75 mL/min/1.73 m2. In multivariable analysis, a higher eGFRcr was associated with lower odds (0.59 [0.50, 0.68] per 10 mL/min/1.73 m2 increase) of eGFRcys substantially exceeding eGFRcr; a higher BMI was also associated with this outcome, while ART regimens inhibiting tubular secretion of creatinine were not predictive. Of the 22 participants with eGFRcr 45–60 mL/min/1.73 m2, 16 (73%) had eGFRcys >60 mL/min/1.73 m2. Conclusions: We report substantially higher eGFRcys than eGFRcr in a subset of people of African ancestry with suppressed HIV, particularly among those with eGFRcr 45–75 mL/min/1.73 m2. In this population, eGFRcys provides clinically useful information irrespective of ART regimen.
- 1 February 2025
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 98 (2) , 171-175
Open AccessBrief Report: Cystatin C Provides Substantially Higher Glomerular Filtration Rate Estimates Than Creatinine in a Subset of Black People With HIV on Current Antiretroviral Regimens
Background: In African populations, estimated glomerular filtration rate by cystatin C (eGFRcys) is better aligned with gold-standard GFR measurements than eGFR by creatinine (eGFRcr). Moreover, eGFRcys is unaffected by the effects of antiretroviral therapy (ART) on tubular secretion and may thus provide better estimates of GFR in people with HIV on ART. Setting: Observational cohort study of people of African ancestry living with suppressed HIV RNA on ART in London, United Kingdom. Methods: Cross-sectional analysis of 360 paired serum creatinine and cystatin C measurements. Participants whose eGFRcys substantially (>10%) exceeded eGFRcr were identified, and factors associated with this outcome were identified in logistic regression analysis. Results: The median age of participants was 52 years, 56% were women, and 82% born in Africa or the Caribbean. The eGFRcys substantially exceeded eGFRcr in 42% of participants in the overall cohort, and in 68% of those with eGFRcr 45–75 mL/min/1.73 m2. In multivariable analysis, a higher eGFRcr was associated with lower odds (0.59 [0.50, 0.68] per 10 mL/min/1.73 m2 increase) of eGFRcys substantially exceeding eGFRcr; a higher BMI was also associated with this outcome, while ART regimens inhibiting tubular secretion of creatinine were not predictive. Of the 22 participants with eGFRcr 45–60 mL/min/1.73 m2, 16 (73%) had eGFRcys >60 mL/min/1.73 m2. Conclusions: We report substantially higher eGFRcys than eGFRcr in a subset of people of African ancestry with suppressed HIV, particularly among those with eGFRcr 45–75 mL/min/1.73 m2. In this population, eGFRcys provides clinically useful information irrespective of ART regimen.
- Open Access
Long-Term Immune Consequences of Initial SARS-CoV-2 A.23.1 Exposure: A Longitudinal Study of Antibody Responses and Cross-Neutralization in a Ugandan Cohort
Background: This study assessed the long-term dynamics of neutralizing antibodies in a Ugandan cohort primarily exposed to the A.23.1 SARS-CoV-2 variant, examining how this shaped immune breadth and potency against diverse strains following infection and prototype-based vaccination. Methods: We conducted a 427-day retrospective analysis of 41 participants across multiple SARS-CoV-2 waves, assessing binding and neutralizing antibody responses using in-house ELISA and pseudotyped virus neutralization assays. We quantified immune responses to key SARS-CoV-2 variants, A.23.1, D614G, Delta, and BA.4, capturing evolving immunity across the pandemic. Results: Neutralizing antibody titers against A.23.1 remained significantly higher than those against D614G, Delta, and BA.4, highlighting the solid immune memory following A.23.1 infection. Consistently lower titers were observed for BA.4 across all time points, aligning with its strong immune-evasion capability. Correlations between neutralizing titers and spike-directed IgG (S-IgG) concentrations were significantly stronger for A.23.1 than for D614G, with no correlation for BA.4. ChAdOx1-S vaccination substantially elevated the neutralizing titers across all variants, most notably BA.4, highlighting the essential role of vaccination in boosting immunity, even in individuals with initially low titers. Conclusions: Initial exposure to the A.23.1 variant triggered potent immune responses, shaping neutralizing antibody dynamics during subsequent exposures. These findings highlight the importance of accounting for early viral exposures in vaccine development and public health planning. The distinctly lower immune response to BA.4 highlights the need for continuous antigenic monitoring and timely vaccine updates for protection against emerging variants. Vaccination remains essential for reinforcing and sustaining immunity against evolving variants.
Open AccessLong-Term Immune Consequences of Initial SARS-CoV-2 A.23.1 Exposure: A Longitudinal Study of Antibody Responses and Cross-Neutralization in a Ugandan Cohort
Background: This study assessed the long-term dynamics of neutralizing antibodies in a Ugandan cohort primarily exposed to the A.23.1 SARS-CoV-2 variant, examining how this shaped immune breadth and potency against diverse strains following infection and prototype-based vaccination. Methods: We conducted a 427-day retrospective analysis of 41 participants across multiple SARS-CoV-2 waves, assessing binding and neutralizing antibody responses using in-house ELISA and pseudotyped virus neutralization assays. We quantified immune responses to key SARS-CoV-2 variants, A.23.1, D614G, Delta, and BA.4, capturing evolving immunity across the pandemic. Results: Neutralizing antibody titers against A.23.1 remained significantly higher than those against D614G, Delta, and BA.4, highlighting the solid immune memory following A.23.1 infection. Consistently lower titers were observed for BA.4 across all time points, aligning with its strong immune-evasion capability. Correlations between neutralizing titers and spike-directed IgG (S-IgG) concentrations were significantly stronger for A.23.1 than for D614G, with no correlation for BA.4. ChAdOx1-S vaccination substantially elevated the neutralizing titers across all variants, most notably BA.4, highlighting the essential role of vaccination in boosting immunity, even in individuals with initially low titers. Conclusions: Initial exposure to the A.23.1 variant triggered potent immune responses, shaping neutralizing antibody dynamics during subsequent exposures. These findings highlight the importance of accounting for early viral exposures in vaccine development and public health planning. The distinctly lower immune response to BA.4 highlights the need for continuous antigenic monitoring and timely vaccine updates for protection against emerging variants. Vaccination remains essential for reinforcing and sustaining immunity against evolving variants.
- Open Access
- 6 January 2025
- Published by MDPI AG in Preprints.org
Long-Term Immune Consequences of Initial SARS-CoV-2 A.23.1 Exposure: A Longitudinal Study of Antibody Responses and Cross-Neutralisation in a Ugandan Cohort
Background: This study assessed the long-term dynamics of neutralising antibodies in a Ugandan cohort primarily exposed to the A.23.1 SARS-CoV-2 variant, examining how this shaped immune breadth and potency against diverse strains following infection and prototype-based vaccination. Methods: We conducted a 427-day retrospective analysis of 41 participants across multiple SARS-CoV-2 waves, assessing binding and neutralising antibody responses using in-house ELISA and pseudotyped virus neutralisation assays. We quantified immune responses to key SARS-CoV-2 variants, A.23.1, D614G, Delta, and BA.4, capturing evolving immunity across the pandemic. Results: Neutralising antibody titres against A.23.1 remained significantly higher than those against D614G, Delta, and BA.4, highlighting the solid immune memory following A.23.1 infection. Consistently lower titres were observed for BA.4 across all time points, aligning with its strong immune-evasion capability. Correlations between neutralising titres and spike-directed IgG (S-IgG) concentrations were significantly stronger for A.23.1 than for D614G, with no correlation for BA.4. ChAdOx1-S vaccination substantially elevated the neutralising titres across all variants, most notably BA.4, highlighting the essential role of vaccination in boosting immunity, even in individuals with initially low titres. Conclusions: Initial exposure to the A.23.1 variant triggered potent immune responses, shaping neutralising antibody dynamics during subsequent exposures. These findings highlight the importance of accounting for early viral exposures in vaccine development and public health planning. The distinctly lower immune response to BA.4 highlights the need for continuous antigenic monitoring and timely vaccine updates for protection against emerging variants. Vaccination remains essential, reinforcing and sustaining im-munity against evolving variants.
- 6 January 2025
- Published by MDPI AG in Preprints.org
Open AccessLong-Term Immune Consequences of Initial SARS-CoV-2 A.23.1 Exposure: A Longitudinal Study of Antibody Responses and Cross-Neutralisation in a Ugandan Cohort
Background: This study assessed the long-term dynamics of neutralising antibodies in a Ugandan cohort primarily exposed to the A.23.1 SARS-CoV-2 variant, examining how this shaped immune breadth and potency against diverse strains following infection and prototype-based vaccination. Methods: We conducted a 427-day retrospective analysis of 41 participants across multiple SARS-CoV-2 waves, assessing binding and neutralising antibody responses using in-house ELISA and pseudotyped virus neutralisation assays. We quantified immune responses to key SARS-CoV-2 variants, A.23.1, D614G, Delta, and BA.4, capturing evolving immunity across the pandemic. Results: Neutralising antibody titres against A.23.1 remained significantly higher than those against D614G, Delta, and BA.4, highlighting the solid immune memory following A.23.1 infection. Consistently lower titres were observed for BA.4 across all time points, aligning with its strong immune-evasion capability. Correlations between neutralising titres and spike-directed IgG (S-IgG) concentrations were significantly stronger for A.23.1 than for D614G, with no correlation for BA.4. ChAdOx1-S vaccination substantially elevated the neutralising titres across all variants, most notably BA.4, highlighting the essential role of vaccination in boosting immunity, even in individuals with initially low titres. Conclusions: Initial exposure to the A.23.1 variant triggered potent immune responses, shaping neutralising antibody dynamics during subsequent exposures. These findings highlight the importance of accounting for early viral exposures in vaccine development and public health planning. The distinctly lower immune response to BA.4 highlights the need for continuous antigenic monitoring and timely vaccine updates for protection against emerging variants. Vaccination remains essential, reinforcing and sustaining im-munity against evolving variants.
- Open Access
- 13 December 2024
- Published by AOSIS in Journal of Public Health in Africa
- Vol. 16 (1) , 11
Understanding sexual violence: Perspectives from an adolescent HIV prevention study
Background: Sub-Saharan Africa has a high prevalence of sexual violence in young women, with less data on young men.Aim: We investigated the prevalence of forced sex among adolescents and young people and described factors putting them at risk of sexual violence.Setting: The study was conducted in South Africa, Uganda and Zimbabwe.Methods: We conducted a cross-sectional, structured survey among 1330 13–24-year-old male and female participants. Logistic regression models were used to estimate odds ratios for associations with forced sex, adjusting for site, sex and age. Sixty in-depth interviews and 24 group discussions were also conducted. Data were transcribed, translated and analysed using thematic framework analysis.Results: Seventy-six out of 1326 participants (6%) reported forced sex in the last 6 months. Forced sex was most commonly reported in Entebbe versus other sites, female than male participants, and 18–24 years than 13–18 years. Associations were seen with younger sexual debut (adjusted odds ratio [aOR]: 0.89; 95% confidence interval [CI]: 0.81, 0.98), ever having transactional sex (aOR: 2.18; 95% CI: 1.19, 4.02), risk-taking (aOR: 3.51; 95% CI: 1.99, 6.19), depression (aOR: 3.20; 95% CI: 1.69, 6.06), anxiety (aOR: 2.07; 95% CI: 1.08, 3.96) and binge drinking (aOR: 2.66; 95% CI: 1.33, 5.36), and strong association with forcing someone to have sex (aOR: 7.54; 95% CI: 3.68, 15.46). Qualitative data support these results.Conclusion: Our findings identify risks similar to those for sexual violence.Contribution: We suggest protection strategies to police times and places of risk are developed, and addressed in economic and legal country specific guidance.
- 13 December 2024
- Published by AOSIS in Journal of Public Health in Africa
- Vol. 16 (1) , 11
Open AccessUnderstanding sexual violence: Perspectives from an adolescent HIV prevention study
Background: Sub-Saharan Africa has a high prevalence of sexual violence in young women, with less data on young men.Aim: We investigated the prevalence of forced sex among adolescents and young people and described factors putting them at risk of sexual violence.Setting: The study was conducted in South Africa, Uganda and Zimbabwe.Methods: We conducted a cross-sectional, structured survey among 1330 13–24-year-old male and female participants. Logistic regression models were used to estimate odds ratios for associations with forced sex, adjusting for site, sex and age. Sixty in-depth interviews and 24 group discussions were also conducted. Data were transcribed, translated and analysed using thematic framework analysis.Results: Seventy-six out of 1326 participants (6%) reported forced sex in the last 6 months. Forced sex was most commonly reported in Entebbe versus other sites, female than male participants, and 18–24 years than 13–18 years. Associations were seen with younger sexual debut (adjusted odds ratio [aOR]: 0.89; 95% confidence interval [CI]: 0.81, 0.98), ever having transactional sex (aOR: 2.18; 95% CI: 1.19, 4.02), risk-taking (aOR: 3.51; 95% CI: 1.99, 6.19), depression (aOR: 3.20; 95% CI: 1.69, 6.06), anxiety (aOR: 2.07; 95% CI: 1.08, 3.96) and binge drinking (aOR: 2.66; 95% CI: 1.33, 5.36), and strong association with forcing someone to have sex (aOR: 7.54; 95% CI: 3.68, 15.46). Qualitative data support these results.Conclusion: Our findings identify risks similar to those for sexual violence.Contribution: We suggest protection strategies to police times and places of risk are developed, and addressed in economic and legal country specific guidance.